A pair of late-stage biotechs submitted IPO plans last week as industry insiders gear up for what could be a handful of post-Labor Day public debut pitches.
To repeat: That’s a handful of IPOs, not an overflowing basket of filings like the days of 2021 that saw at least 100…
Click here to view original post
